Mantis
Winter 2026 NewDigital Twins of humans
Mantis is a digital twin company that combines LLMs with high-fidelity physics simulations in order to convert rare and difficult-to-access human behavior data into predictive models.
AI Investor Summary
Mantis is building AI-powered digital twins of humans by integrating LLMs with physics simulations to generate predictive models from rare behavioral data. Led by a highly accomplished repeat founder, the company is targeting the massive healthcare and life sciences market, having already secured significant seed funding. The key challenge lies in establishing trust and validating the accuracy of these synthetic models for critical applications.
Key Highlights
- ● Exceptional founder with a proven track record and unique interdisciplinary background.
- ● Addresses a massive and growing market in healthcare and life sciences with AI-driven solutions.
- ● Significant seed funding secured ($7.4M) and positive early press.
Risk Factors
- ● The core challenge of building trust and ensuring the accuracy/validity of digital twins for critical medical applications.
- ● The technical complexity of integrating LLMs with high-fidelity physics simulations at scale.
- ● Dependence on the founder's leadership and vision, with limited information on the rest of the team's depth.
Founders
I'm an Ex-elite ice climber turned repeat computer science / biomedical founder. After bringing climbing to an Olympic stage (Lilihammer 2016), breaking 8 world records, and developing the sport of ice climbing, I dropped out of high school, got a degree in CS from Harvey Mudd, was a founding engineer for a sports tech company, founded a YC company (Louiza Labs), and earned a master's in Bioengineering.
Score Breakdown
Georgia Witchel is an exceptionally strong founder with a unique blend of technical depth (CS, Bioengineering, PhD in Biochemistry), entrepreneurial experience (repeat founder, YC alum), and domain expertise (Genentech, UCSF). Her background in elite sports and record-breaking achievements suggests immense drive and problem-solving ability. The rest of the team is not detailed, but Georgia's profile alone elevates the team score significantly. [Boost +1: PhD from Berkeley]
The market for synthetic patient data and predictive human behavior modeling is enormous, touching healthcare research, drug discovery, and personalized medicine. The growth rate is high due to advancements in AI and the increasing need for efficient, ethical data generation. Timing is opportune with the rise of LLMs and the demand for better R&D tools. Regulatory tailwinds exist as the industry seeks ways to accelerate drug development and improve patient outcomes, though data privacy and validation remain key considerations.
The combination of LLMs and high-fidelity physics simulations for human behavior is technically differentiated and defensible if executed well. This approach could create a strong moat by generating unique, high-quality data. However, the 'UX quality' is unknown, and the 'platform potential' is yet to be demonstrated. The core challenge will be in validating the accuracy and trustworthiness of these digital twins for critical applications in healthcare.
The company has secured a $7.4 million seed round, which is a strong signal of investor interest. Positive press coverage indicates early validation and market awareness. However, specific metrics on revenue, users, or growth rate are not provided, making it difficult to assess current commercial traction beyond funding. [Boost +3: Tier-1 VC: accel; Major press: techcrunch]
News
Mantis Biotech has raised $7.4 million in seed funding to build physics-based digital twins of the human body, addressing data scarcity in medicine by creating synthetic datasets for research and development.
Mantis Biotech has raised $7.4 million in seed funding to build physics-based digital twins of humans, aiming to generate synthetic data for healthcare research where real patient data is scarce or unusable.
Mantis Biotech is creating AI-powered 'digital twins' of the human body using large language models and physics-based simulations to generate synthetic datasets for biomedical research, addressing data limitations in areas like rare diseases.
Mantis Biotech is developing 'digital twins' of humans using physics-based predictive models and LLM-based systems to simulate and predict medical issues, aiming to address data scarcity in medicine and finding initial success in professional sports.
Mantis Biotech has raised $7.4 million in seed funding to develop physics-based digital twins of humans, aiming to generate synthetic data that can fill gaps in scarce or unusable real patient data for drug research, clinical modeling, and preventive healthcare.
Mantis Biotech has raised $7.4 million to create physics-based digital twins of humans, generating synthetic data to address scarcity in medical research, with a focus on drug research, clinical modeling, and preventive healthcare.
Mantis, a Y Combinator Winter 2026 startup, is developing physics-enhanced datasets for low-resource machine learning, focusing on clinical trial data quality with a strong founder signal and significant market opportunity.
Mantis Biotech has raised a total of $6.3M from 1 Seed round on Nov 17, 2025, with lead investors including Decibel and StoryHouse Ventures.
Mantis Biotech offers a domain-aware data platform for life sciences that encodes biological, clinical, and human-performance meaning directly into reusable datasets, aiming to prevent data inaccuracies that delay clinical trials.
Mantis is a Y Combinator Winter 2026 startup focused on creating digital twins of humans by combining LLMs with physics simulations to convert rare human behavior data into predictive models.
Mantis Biotech, a company creating human-in-computer models, has announced a $6.3 million seed round led by Decibel Partners to unify complex data into a single platform for actionable insights.
Mantis Biotech is developing a platform that uses LLMs and physics simulations to create digital twins of the human body, aiming to solve data scarcity issues in biomedical research and applications.
Mantis Biotech offers a domain-aware data platform for life sciences that encodes biological and clinical meaning into reusable datasets, aiming to prevent data inaccuracies that delay clinical trials.
Mantis Biotech has secured $7.4 million in seed funding led by Decibel VC to develop AI-powered synthetic data infrastructure for biomedical applications, focusing on creating high-fidelity digital twins of the human body.
Quick Info
- Batch
- Winter 2026
- Team Size
- 3
- Location
- Unspecified
- Founders
- 1
- Scraped
- 4/10/2026